Bristol-Myers Squibb Company (BMY)
Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?
BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.
2 Wonderful Dividends At Bargain Basement Prices
Uncertainty creates value opportunities. In this article, I highlight two value stocks trading far below their historical valuations. Both offer dividend yields that are well above historical average and strong growth potential. Both stocks exemplify how investors can secure decent yields and future upside by buying quality companies when market sentiment is overly pessimistic.
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Boomers Are Grabbing These Big Beautiful Blue-Chip Dividend Giants For Decades of Passive Income
Blue-chip dividend stocks are shares of large, well-established, financially stable companies with a consistent and reliable performance history.
Will The Decline in Legacy Drugs Pull Down BMY's Top Line?
Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer growth portfolio.
Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note
Bristol Myers Squibb (BMY) closed at $47.51 in the latest trading session, marking a +2.64% move from the prior day.
Bristol-Myers Squibb: Strong Launch Portfolio Amid Market Reset
Initiate Bristol-Myers Squibb (BMY) with Buy and $57 PT, driven by high-momentum launches, robust pipeline, and underappreciated growth portfolio outperformance. BMY's $13bn+ annual FCF, strong balance sheet, and disciplined capital returns provide downside protection and support ongoing R&D and M&A activity. Our above-consensus FY25/26 revenue forecasts reflect accelerating adoption of Opdivo, Cobenfi, and Camzyos, offsetting legacy product erosion and regulatory headwinds.
BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?
BMY loses 16.3% YTD as pipeline setbacks and generic pressure offset gains from new drug approvals and sales.
Time to Sell the Rally and Buy These 5% and Higher Blue-Chip Dividend Giants
Investors love dividend stocks, especially the blue-chip variety, because they offer a significant income stream and have massive total return potential.
Bristol-Myers Squibb: You Might Wish You Bought More Now (Upgrade)
Bristol-Myers Squibb faces structural headwinds from legacy product losses, but its strong free cash flow and undervalued stock price provide downside protection. The recent $11B partnership with BioNTech signals management's ambition to revitalize growth and address long-term potential in oncology. Despite near-term 'dead money' concerns, BMY's deeply discounted valuation, while paying more than 5% in dividend yield offers an attractive margin of safety.
5 of the Safest Strong-Buy High-Yield Dividend Stocks Are On Sale Now
Investors love dividend stocks, especially high-yield ones, because they offer a significant income stream and have substantial total return potential.
This Once Dominant Dividend Stock May Be About to Come Back to Life in July
For income investors seeking a timely value stock to buy on the dip, former dividend darling Bristol-Myers Squibb (NYSE:BMY) may fit the bill as one of the top names to watch in the month of July.
